Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1357

Shown on this page

Current sort

Live official records

Conditions: Microvascular Inflammation
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Loma Linda, California • Los Angeles, California • Orange, California + 18 more

Conditions: Von Hippel-Lindau Disease, Malignant Neoplasms
Interventions: Belzutifan, Nivolumab, Lenvatinib, Cabozantinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 7
States / cities: Boston, Massachusetts • Detroit, Michigan • Philadelphia, Pennsylvania + 3 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Empasiprubart IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 13
States / cities: Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 9 more

Conditions: Treatment Resistant Depression
Interventions: Sham-stimulation, Active-stimulation; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more

Conditions: Frailty, Lung Tranplant Candidate
Interventions: XFIT; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: San Francisco, California • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Brain Death, Respiration, Artificial
Interventions: Hope inVent; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 1 Year to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, HER3-DXd; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Lexington, Kentucky • Baltimore, Maryland • Fargo, North Dakota + 2 more

Conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer
Interventions: Nadofaragene Firadenovec; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 54
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Renal Denervation (Symplicity Spyral™); Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 76
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
Interventions: Carboplatin, Mirvetuximab Soravtansine, Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 64 more

Conditions: Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Interventions: LivIQ Leadless Pacemaker System; Device
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Burlingame, California • La Jolla, California • Laguna Hills, California + 20 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 342
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 262 more

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists: ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Penn Medicine (University of Pennsylvania)

Filter and sort this campus

Live official records

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Exercise-based Frailty Intervention in Lung Transplantation (XFIT)

Miniature In-line Respirator

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

About this Penn Medicine (University of Pennsylvania) institution page